All News

28 April 2008

MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 ProgramAntibodies

24 April 2008

Arana and Kyowa Hakko to co-develop anti-cancer drugAntibodies

24 April 2008

MorphoSys and the Leibniz-Institut für Molekulare Pharmakologie Sign Broad Research PartnershipAntibodies

24 April 2008

ESBATech’s Lead Antibody Fragment Enters Clinical Development for Ophthalmic IndicationsAntibodies

23 April 2008

Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid TumorsAntibodies

23 April 2008

ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast CancerAntibodies

23 April 2008

Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate StudyAntibodies

22 April 2008

CimziaA(R) Approved in the US for the Treatment of Moderate to Severe Crohn’s DiseaseAntibodies

22 April 2008

Human Genome Sciences completes enrollment in first of two phase 3 LYMPHOSTAT-B(R) trialsAntibodies

21 April 2008

Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid ArthritisAntibodies

21 April 2008

Cancer Treatment Pioneer, Lpath, Initiates Dosing in Phase 1 Cancer TrialAntibodies

20 April 2008

Genentech Provides Update on “AVAiL” Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung CancerAntibodies

17 April 2008

Actemra approved in Japan to treat patients with rheumatoid arthritisAntibodies

16 April 2008

Human Genome Sciences Advances Oncology PortfolioAntibodies

16 April 2008

Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research MeetingAntibodies

16 April 2008

HUMIRA(R) received approval for the treatment of rheumatoid arthritis in JapanAntibodies

16 April 2008

Data presented at the 60th Annual Meeting of the American Academy of Neurology offers additional support for plasma exchange as a potential tool to accelerate Tysabri (R) removalAntibodies

16 April 2008

Medarex Reports Preclinical Data on Multiple Antibody-Drug Conjugate Candidates at American Association for Cancer Research MeetingAntibodies

15 April 2008

Amgen Presents Preclinical and Clinical Data from Oncology ProgramsAntibodies

15 April 2008

Preclinical Study Presented at AACR Annual Meeting Shows Peregrine’s Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer ModelAntibodies

15 April 2008

Preclinical data presented for Active Biotech’s ANYARA technologyAntibodies

15 April 2008

Seattle Genetics Presents Preclinical Data on its Antibody-Drug Conjugate Technology and SGN-33 Program at AACRAntibodies

15 April 2008

MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13Antibodies

15 April 2008

Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research MeetingAntibodies

14 April 2008

Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple SclerosisAntibodies

14 April 2008

Cell Genesys Reports Preclinical Data Demonstrating Superior Anti-Tumor Immunity for Multiantigen Compared to Single-Antigen ImmunotherapiesAntibodies

14 April 2008

Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate StudyAntibodies

14 April 2008

PDL BioPharma Announces Data Presentations for Antibody Pipeline ProductsAntibodies

14 April 2008

Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and MelanomaAntibodies

14 April 2008

Immunomedics Reports Veltuzumab Enhances Radioimmunotherapy With Epratuzumab in Lymphoma ModelAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

FcRn Inhibitors Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

Report Package: Bispecific Antibodies

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

CD38-Targeted Antibody & Cell Therapy Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis